BaroPace’s latest clinical research has been accepted for publication in The American Journal of Cardiology — one of cardiology’s most prestigious peer-reviewed journals.
The study, “Blood Pressure–Adaptive Atrial Pacing Narrows Pulse Pressure in Hypertensive HFpEF,” reports that PressurePace™ therapy selectively narrowed pulse pressure and improved diastolic blood pressure in HFpEF patients — without affecting systolic blood pressure — while also improving exercise capacity and quality of life.
This is BaroPace’s third peer-reviewed publication and adds to a growing body of clinical evidence supporting PressurePace™ as a novel treatment approach for heart failure with preserved ejection fraction.
Full citation forthcoming upon publication.
